-

Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline

In collaboration with AbbVie, initiation of preclinical and supportive CMC* work to advance a first Long-Acting Injectable candidate into clinical development

MONTPELLIER, France--(BUSINESS WIRE)--Collaboration with AbbVie

  • Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development

Collaboration with Teva

  • UZEDY® (risperidone LAI)
  • Reaffirming revenue guidance for 2024 by Teva: c.$80 million
  • Exploring an additional indication for the treatment of Bipolar I Disorder in adults
  • Olanzapine LAI
  • No PDSS** observed after completion of c.95% of the targeted injections for submission (July 31, 2024)
  • Full phase 3 safety results on track for H2 2024

Other in-house and partnered assets

  • mdc-CWM (post operative pain): ongoing review of completed phase 3 study by Medincell partner Arthritis Innovation Corporation (AIC) with plans to meet with FDA in Q4 2024 to discuss additional studies required for approval
  • mdc-WWM (contraception): CMC activities ongoing for initiation of clinical phase 1 activities in 2025
  • mdc-STM (malaria): CMC activities ongoing for initiation of clinical phase 1 activities in 2025
  • Over 10 in-house or partnered active programs currently at formulation stage

ACCESS HERE FOR THE FULL PRESS RELEASE

*CMC (Chemistry, Manufacturing, and Controls) in the pharmaceutical industry refers to the essential documentation and processes related to the chemical composition, manufacturing methods, and quality control measures of a drug, ensuring it meets regulatory standards for safety, efficacy, and quality.

**PDSS = Post injection Delirium/Sedation Syndrome

Contacts

David Heuzé - Head of Corporate and Financial Communications, and ESG
david.heuze@medincell.com / +33 (0)6 83 25 21 86

Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023

Investors Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94

Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé - Head of Corporate and Financial Communications, and ESG
david.heuze@medincell.com / +33 (0)6 83 25 21 86

Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023

Investors Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94

Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simultaneously in Engli...

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simult...

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: Jefferies Annual NY Biotech Conference Dates: June 2-4, 2026 Location: New-York Presentation: 9:55 AM ET Jun...
Back to Newsroom